Yi-An Chu Sells Shares of Apollomics, Inc. (APLM)
Yi-An Chu sold 500 shares of Apollomics, Inc. on June 15, 2026.
Key Points
- Yi-An Chu sold 500 shares of Apollomics, Inc. on June 15, 2026, with no disclosed transaction value.
- Apollomics, Inc. trades at $13.85 with a market cap of approximately $31.8 million and a 52-week range between $3.66 and $42.12.
- CITIGROUP INC and UBS GROUP AG have increased their holdings in Apollomics, while Kestra Advisory Services, LLC exited its position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Yi-An Chu, an insider at Apollomics, Inc. (NasdaqCM: APLM), sold 500 shares of the company on June 15, 2026. Although the transaction didn't have a disclosed value, it reflects a movement in insider holdings at the biotechnology firm.
Other Institutional Activity in Apollomics, Inc.
CITIGROUP INC boosted its holdings by 438 shares, ending with a total of 438 shares worth about $6,811. UBS GROUP AG also increased its stake by 78 shares, bringing its total to 142 shares valued at approximately $2,251. Meanwhile, Kestra Advisory Services, LLC exited its position, reducing its holdings by 4,380 shares.
Apollomics, Inc. Stock Down 45.3%
Shares of Apollomics, Inc. are trading at $13.85. The company has a market cap of about $31.8 million. Its forward P/E is not meaningful due to a lack of profitability, and it has a beta of 1.526. The stock's 52-week range is between $3.66 and $42.12, with a 50-day moving average of $14.25 and a 200-day moving average of $16.91.
Insider Buying and Selling at Apollomics, Inc.
On June 15, 2026, several insiders made transactions at Apollomics, Inc. Chen Hong-Jung and CEO Chen Hung-Wen each bought 500 and 5,000 shares respectively, with no disclosed price. Conversely, insiders Jan Chen-Huan and Tsai Hsien-Shu sold 500 shares each, also with no price stated. COO Chen Yi-Kuei sold 5,000 shares.
Analysts Set New Price Targets
H.C. Wainwright reiterated its 'buy' rating on Apollomics, Inc. with various target prices, including $2.00 on May 8, 2024, and $17.00 on November 20, 2023. EF Hutton maintained a 'buy' rating with a target of $25.00 on May 25, 2023.
About Apollomics, Inc.
Apollomics, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California. The company focuses on developing oncology therapies that harness the immune system and target specific molecular pathways to treat cancer. Its product lineup includes Vebreltinib, a c-Met inhibitor, and APL-102, a tyrosine kinase inhibitor, among others. Founded in 2015, Apollomics aims to advance cancer treatment through innovative drug development.
Bottom Line
Yi-An Chu's recent share sale at Apollomics, Inc. is part of broader insider activity at the company. Investors often watch these transactions for insights into insider sentiment. It's important to remember that 13F filings and insider transactions are historical and may not reflect current holdings or strategies.
Get Apollomics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APLM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.